Alnylam Pharmaceuticals financials
$254.07−0.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844.3M | $492.9M | $219.8M | $74.9M | $89.9M | $47.2M |
| Gross profit | $3.04B | $1.94B | $1.56B | $897.2M | $729.3M | $414.8M | $194.7M | $73.1M | $89.9M | $47.2M |
| Gross margin | 81.8% | 86.4% | 85.3% | 86.5% | 86.4% | 84.2% | 88.6% | 97.6% | 100.0% | 100.0% |
| Operating income | $501.6M | -$176.9M | -$282.2M | -$785.1M | -$708.7M | -$828.4M | -$939.4M | -$814.7M | -$500.1M | -$424.6M |
| Net income | $313.7M | -$278.2M | -$440.2M | -$1.13B | -$852.8M | -$858.3M | -$886.1M | -$761.5M | -$490.9M | -$410.1M |
| Net margin | 8.4% | −12.4% | −24.1% | −109.0% | −101.0% | −174.1% | −403.2% | −1016.6% | −545.9% | −869.6% |
| Diluted EPS | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | $-7.57 | $-5.42 | $-4.79 |
| EBITDA | $557.2M | -$120.2M | -$228.1M | -$740.6M | -$661.1M | -$793.7M | -$922.3M | -$799.4M | -$488.2M | -$409.5M |
| Operating cash flow | $524.1M | -$8.3M | $104.2M | -$541.3M | -$641.7M | -$615.0M | -$278.4M | -$562.6M | -$382.8M | -$307.7M |
| Free cash flow | $465.4M | -$42.6M | $41.9M | -$613.3M | -$718.1M | -$685.3M | -$418.6M | -$689.5M | -$487.0M | -$372.3M |
| Diluted shares | 134.7M | 127.7M | 124.9M | 121.7M | 118.5M | 115.0M | 109.3M | 100.6M | 90.6M | 85.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.66B | $966.4M | $812.7M | $866.4M | $820.0M | $496.6M |
| Short-term investments | $1.25B | $1.73B | $1.63B | $1.33B | $1.62B | $1.38B |
| Total debt | $1.01B | $1.02B | $1.02B | $1.02B | $675.7M | $191.3M |
| Total assets | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B |
| Total liabilities | $4.18B | $4.17B | $4.05B | $3.70B | $3.06B | $2.39B |
| Shareholders' equity | $789.2M | $67.1M | -$220.6M | -$158.2M | $588.2M | $1.02B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology